drugset / Trial / NCT00760344
Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to determine the efficacy and safety of SYR-472, once daily (QD), in subjects with type 2 diabetes mellitus who have not achieved glycemic control with diet and exercise, or by taking metformin.
Timeline
- Start
- 2007-03
- Primary completion
- 2008-03
- Completion
- 2008-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Sitagliptin | Small molecule | 100 mg | Oral |
| Subject | Trelagliptin | Small molecule | 3.125 mg | Oral |
| Subject | Trelagliptin | Small molecule | 12.5 mg | Oral |
| Subject | Trelagliptin | Small molecule | 50 mg | Oral |
| Subject | Trelagliptin | Small molecule | 100 mg | Oral |